Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis

Journal of Inflammation (United Kingdom)

Volumn 9, Issue , 2012, Pages

  Soltys, Jindrich ^a   Wu, Xiaobo ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine receptor (AChR); Adaptive immune response; Complement receptor 1 related gene protein y deficiency (Crry ); Experimental autoimmune myasthenia gravis (EAMG)

Indexed keywords

CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR 1 RELATED PROTEIN Y; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CRRY GENE; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE INACTIVATION; GRIP STRENGTH; IMMUNOFLUORESCENCE TEST; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; MUSCLE EXAMINATION; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; SCORING SYSTEM; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALIA; MUS;

EID: 84861468854     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-9-20     Document Type: Article

References (40)

1. Myasthenia gravis: past, present, and future. Conti-Fine BM, Milani M, Kaminski HJ, J Clin Invest 2006 116 2843 2854 (Pubitemid 44684466)
2. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. Lennon VA, Seybold ME, Lindstrom JM, Cochrane C, Ulevitch R, J Exp Med 1978 147 973 983 (Pubitemid 8318067)
3. C5 gene influences the development of murine myasthenia gravis. Christadoss P, J Immunol 1988 140 2589 2592
4. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. Tuzun E, Scott BG, Goluszko E, Higgs S, Christadoss P, J Immunol 2003 171 3847 3854 (Pubitemid 37264927)
5. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Nakano S, Engel AG, Neurology 1993 43 1167 1172 (Pubitemid 23177718)
6. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. Sahashi K, Engel AG, Lambert EH, Howard FM Jr, J Neuropathol Exp Neurol 1980 39 160 172 (Pubitemid 10141862)
7. Soluble terminal complement components in human myasthenia gravis. Barohn RJ, Brey RL, Clin Neurol Neurosurg 1993 95 285 290 (Pubitemid 23344771)
8. The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. Romi F, Kristoffersen EK, Aarli JA, Gilhus NE, J Neuroimmunol 2005 158 191 194 (Pubitemid 39626086)
9. Acquired Autoimmune Myasthenia Gravis. Engel AG, Engel AG, Franzini-Armstrong C (eds) Myology. Volume 2 McGraw-Hill, New York 2004 p 1755 1789
10. Complement: coming full circle. Le Friec G, Kemper C, Arch Immunol Ther Exp 2009 57 393 407
11. Complement deficiency and disease. Unsworth DJ, J Clin Pathol 2008 61 1013 1017
12. Innate immunity in the nervous system. Ramaglia V, Baas F, Prog Brain Res 2009 175 95 123
13. Complement regulatory proteins and autoimmunity. Song WC, Autoimmunity 2006 39 403 410
14. Membrane protein Crry maintains homeostasis of the complement system. Wu X, Spitzer D, Mao D, Peng SL, Molina H, Atkinson JP, J Immunol 2008 181 2732 2740
15. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM, J Exp Med 1995 181 151 159
16. The murine complement regulator Crry: new insights into the immunobiology of complement regulation. Molina H, Cell Mol Life Sci 2002 59 220 229 (Pubitemid 34169510)
17. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M, Nat Genet 2002 31 424 428 (Pubitemid 35154455)
18. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Ruseva MM, Hughes TR, Donev RM, Sivasankar B, Pickering MC, Wu X, Harris CL, Morgan BP, Mol Immunol 2009 46 803 811
19. Complement regulatory protein Crry/p65-mediated signaling in T lymphocytes: role of its cytoplasmic domain and partitioning into lipid rafts. Jimenez-Perianez A, Ojeda G, Criado G, Sanchez A, Pini E, Madrenas J, Rojo JM, Portoles P, J Leukoc Biol 2005 78 1386 1396 (Pubitemid 41779245)
20. A critical role for murine complement regulator crry in fetomaternal tolerance. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H, Science 2000 287 498 501
21. Experimental autoimmune myasthenia gravis in the mouse. Wu B, Goluszko E, Christadoss P, Curr Protoc Immunol 2001 Chapter 15 Unit 15 18
22. Experimental autoimmune myasthenia gravis in the mouse. Wu B, Goluszko E, Huda R, Tuzun E, Christadoss P, Curr Protoc Immunol 2011 Chapter 15 Unit15 23
23. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mastellos D, Prechl J, Laszlo G, Papp K, Olah E, Argyropoulos E, Franchini S, Tudoran R, Markiewski M, Lambris JD, Erdei A, Mol Immunol 2004 40 1213 1221 (Pubitemid 38210273)
24. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor. Molina H, Miwa T, Zhou L, Hilliard B, Mastellos D, Maldonado MA, Lambris JD, Song WC, Blood 2002 100 4544 4549 (Pubitemid 35429696)
25. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, Christadoss P, Sarvetnick N, J Exp Med 1997 186 385 391 (Pubitemid 27332896)
26. IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: Up-regulation of muscle IL-15 by IL-4. Shandley S, Martinez S, Krolick K, Clin Immunol 2009 132 246 256
27. Different age-related effects of thymectomy in myasthenia gravis: role of thymoma, zinc, thymulin, IL-2 and IL-6. Mocchegiani E, Giacconi R, Muzzioli M, Gasparini N, Provinciali L, Spazzafumo L, Licastro F, Mech Ageing Dev 2000 117 79 91 (Pubitemid 30665795)
28. Inhibition of IL-6 overproduction by steroid treatment before transsternal thymectomy for myasthenia gravis: does it help stabilize perioperative condition? Endo S, Hasegawa T, Sato Y, Otani S, Saito N, Tetsuka K, Tezuka Y, Sohara Y, Eur J Neurol 2005 12 768 773 (Pubitemid 41495133)
29. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. Poea-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A, Bidault J, Tzartos S, Berrih-Aknin S, J Immunol 2005 174 5941 5949 (Pubitemid 40663780)
30. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Mu L, Sun B, Kong Q, Wang J, Wang G, Zhang S, Wang D, Liu Y, An H, Li H, Immunology 2009 128 826 e836
31. Decay-accelerating factor modulates induction of T cell immunity. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME, J Exp Med 2005 201 1523 1530 (Pubitemid 40720998)
32. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, Song WC, J Exp Med 2005 201 567 577 (Pubitemid 40289547)
33. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. Pavlov V, Raedler H, Yuan S, Leisman S, Kwan WH, Lalli PN, Medof ME, Heeger PS, J Immunol 2008 181 4580 4589
34. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. Miwa T, Zhou L, Tudoran R, Lambris JD, Madaio MP, Nangaku M, Molina H, Song WC, Mol Immunol 2007 44 139 146 (Pubitemid 44647112)
35. Complement: central to innate immunity and bridging to adaptive responses. Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM, Immunol Lett 2005 97 171 179 (Pubitemid 40326948)
36. Complement and its role in innate and adaptive immune responses. Dunkelberger JR, Song WC, Cell Res 2010 20 34 50
37. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL, Mol Immunol 2008 45 395 405 (Pubitemid 47332640)
38. Prevention of Collagen-Induced Arthritis in Mice Transgenic for the Complement Inhibitor Complement Receptor 1-Related Gene/Protein y. Banda NK, Kraus DM, Muggli M, Bendele A, Holers VM, Arend WP, J Immunol 2003 171 2109 2115 (Pubitemid 36966495)
39. Decay-accelerating factor regulates T-cell immunity in the context of inflammation by influencing co-stimulatory molecule expression on antigen-presenting cells. Fang C, Miwa T, Song WC, Blood 2011
40. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME, Exp Neurol 2004 189 333 342 (Pubitemid 39221825)